Excel version of selected tables from the Quarterly Financial Report Quarterly Highlights Infographic Quarter 1 Earnings Report(Kessan Tanshin) Presentation Quarterly Financial Report Webcast Excel version of selected tables from the Quarterly Financial Report Quarterly Highlights Infographic Archive FY2023 (Ap...
Takeda announced strong financial results for the first quarter of fiscal year 2023. Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing to a core operati...
Earnings Report(Kessan Tanshin) Presentation Quarterly Financial Report Webcast Excel version of selected tables from the Quarterly Financial Report Quarterly Highlights Infographic Reference Materials Clinical Trials Summary(updated May 8, 2025) Epidemiology Data(updated May 8, 2025) ...
“The announcement of our new share buyback program, approved by Takeda’s Board of Directors, demonstrates our commitment to shareholder returns.” FINANCIAL HIGHLIGHTS for FY2024 Q3 YTD Ended December 31, 2024 (Billion yen, except percentages and per share amounts) Core (Non-IFRS) FY2024 Out...
Sustainable Value Report 2023 Learn more Takeda Global Headquarters Learn more Takeda in the US Learn more Takeda’s Global CSR Program Learn more The History of Takeda Learn more Values and Corporate Governance Learn more Takeda Manufacturing - 2021 Facilities of the Year Learn more Take...
multiple new indication approvals and multiple key reimbursement milestones supporting access for an even greater number of patients, all creating new near and longer-term growth opportunity. As a result of this momentum, I am pleased to announce we are increasing our full year 2025 financial guida...
“Takeda’s strong financial performance in Q3 allows us to confirm management guidance for FY2020, with further growth acceleration expected in Q4 as we conclude the fiscal year. Reflecting on the transformation of Takeda over the past few years and the world-class R&D engine we...
Takeda expects that the financial impact on its consolidated operating results for the fiscal year ending March 31, 2023 (FY2022), as a result of the completion of the transaction, is immaterial. There is no change in Takeda’s FY2022 consolidated forecasts for operating results or the manageme...
Costa Saroukos, Chief Financial Officer, Takeda, said, “This announcement continues Takeda’s strong momentum toward optimizing our portfolio for growth by delivering highly-innovative medicines and transformative care in our chosen business areas, as well as meeting our leverage targets. As we contin...
decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ADCETRIS; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developm...